Highly Galactosylated Anti-HER2 Pertuzumab, a Biobetter Antibody (CAT#: BioBet-GA-007ZP) Datasheet

ERBB2

erb-b2 receptor tyrosine kinase 2

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.

NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu

Plasma membrane, Endosome, Nucleus.

Diseases associated with ERBB2 include Glioma Susceptibility 1 and Gastric Cancer.

Its related pathways are Association Between Physico-Chemical Features and Toxicity Associated Pathways and RET signaling.

1.Protein tyrosine kinases are part of several cell surface receptor complexes, but obviously require a co-receptor to which a ligand binds. An essential component of the neurotonin receptor complex, although neurotonin does not interact with it alone. GP30 is a potential ligand for this receptor. Regulate the growth and stability of peripheral microtubules (MTs). After ERBB2 is activated, the memo1-rhoa-991 signaling pathway triggers the phosphorylation of GSK3B on the cell membrane, thereby inhibiting GSK3B. This prevents the phosphorylation of APC and CLASP2, allowing them to bind to the cell membrane. In turn, membrane-bound APC allows MACF1 to localize to the cell membrane, which is necessary for microtubule capture and stabilization. 2.Participate in transcriptional regulation in the nucleus. It is associated with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Participate in CDKN1A transcriptional activation; functions include STAT3 and SRC. Participate in the transcription of rRNA genes through RNA Pol I, and promote protein synthesis and cell growth.

Cancer antibody; Controls and Markers antibody; Signaling Transduction antibody; Circulating Tumor Cells BioMarker antibody

Autophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172).

Perjeta

Approved

Protein Based Therapies
Monoclonal antibody (mAb)

DB06366

380610-27-5

Whole Humanized Antibody

Pertuzumab

Human

Pertuzumab (also known as 2C4, trade name Perjeta) is a recombinant humanized monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 protein (HER2). It was first approved by the FDA in 2012 for the treatment of metastatic HER2-positive breast cancer; in early HER2-positive breast cancer, it is also used in the same combination as a new adjuvant. It was originally discovered and developed by Roche's subsidiary Genentech.

Early Breast Cancer
Inflammatory carcinoma of the breast
Locally Advanced Breast Cancer (LABC)
Metastatic Breast Cancer

2C4 Antibody
MOAB 2C4
Monoclonal Antibody 2C4
Omnitarg
rhuMAb-2C4

K16AIQ8CTM

Pertuzumab is a humanized monoclonal antibody designed to target the extracellular dimerization domain of Her2. At the same time, it can also inhibit the dimerization of other HER family members (HER1, HER2, HER3 and HER4) on the surface of cancer cells. In addition, Pertuzumab also inhibits downstream activation of the PI3K and MAPK pathways. Like trastuzumab, pertuzumab also stimulates antibody-dependent cell-mediated cytotoxicity (ADCC).

Pertuzumab can be used in combination with trastuzumab and docetaxel to treat patients with HER2-positive metastatic breast cancer who have not received anti-HER2 treatment or chemotherapy for metastatic disease.